Effect of Eplerenone on Endothelial Function in Patients With Stable Coronary Heart Disease
The aim of the present study is to investigate wether endothelial dysfunction associated with stable coronary artery disease is altered by selective aldosterone antagonism with Eplerenone as potential anti-inflammatory drug versus placebo.
Additionally we hypothesize that selective aldosterone antagonism reduces systemic inflammatory response such as C-reactive proteine, oxidative stress and pro-inflammatory cytokines.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
Please refer to this study by its ClinicalTrials.gov identifier: NCT00427284
|University Hospital Zurich, Division of Cardiology|
|Zurich, ZH, Switzerland, 8091|
|Principal Investigator:||Frank Ruschitzka, Prof MD||University Hospital Zurich, Division of Cardiology|